TENX News and Press, Tenax Therapeutics Inc. From 09/15/22

MORRISVILLE, N.C., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the week with an overview of the biggest pre-market stock movers for Monday! Stocks are moving today on a reverse split, acquisition news, as well as a mon...

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will host a key opinion leader (KOL) webi...

TNX-201 (oral imatinib modified release tablets) Formulation Development has been Successfully Completed Manufacturing Underway to Support Phase 3 PAH Study (IMPROVE) Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, ...

Tenax Therapeutics (NASDAQ:TENX) enters into a agreement with a single institutional investor for the issuance and sale of 10,596,027 units at a purchase price of $0.755/unit. Each Unit consists of one unregistered pre-funded warrant to purchase one share of the Company’s common s...

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a definitive agreement wi...

Tenax Therapeutics press release (NASDAQ:TENX): FY GAAP EPS of -$1.58 misses by $1.51. Cash, cash equivalents and marketable securities totaled $5.6 million as of December 31, 2021, compared to $6.3 million as of December 31, 2020. Shares -2% PM. For further details see: Tenax Therapeut...

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the year ended December 31, 2...

Presentations Will Feature the Company’s Two Late-Stage Drug Candidates: Imatinib for Treatment of Pulmonary Arterial Hypertension (PAH) and Levosimendan for Treatment of Pulmonary Hypertension Associated with Left Heart Failure (PF-HFpEF) Tenax Therapeutics, Inc. (Na...

MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today ...